Globally, Non-Alcoholic Fatty Liver Disease (NAFLD) is a growing concern, impacting a significant portion of the population.

Liver cirrhosis is a serious condition. It damages the liver over time. Common causes include alcohol, hepatitis, and fatty ...

The global progressive pulmonary fibrosis (PPF) treatment market is projected to be valued at USD 4,044.6 Million in 2025 and is expected to reach USD 8,182.4 Million by 2035, registering a CAGR of 7.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Lung macrophages play a pivotal role in diseases like idiopathic pulmonary fibrosis. Two types of macrophages—the white blood ...

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for ALYFTREK ® (deutivacaftor/tezacaftor/vanzacaftor) for the treatment of people with cystic ...

Chronic kidney disease (CKD) is typically associated with severe fibrosis, the exact pathogenesis of which remains unclear.

With its blockbuster Trikafta set to lose patent protection within the decade, Vertex is strengthening its cystic fibrosis ...

Vertex Pharmaceuticals said on Tuesday its next-generation cystic fibrosis treatment has won European Union approval for a ...

Rentosertib, an AI-generated small molecule targeting Traf2- and Nck-interacting kinase, was safe and improved FVC in ...

Two brothers and two friends take on and wi, an 80-mile Atlantic paddleboard challenge in an effort to provide support for ...